In­di­v­ior agrees to pay out $385M to end years­long Sub­ox­one lit­i­ga­tion and ac­cu­sa­tions it pre­vent­ed gener­ic com­pe­ti­tion

Vir­ginia-based In­di­v­ior will pay out $385 mil­lion to bring an end to lit­i­ga­tion over ac­cu­sa­tions it pre­vent­ed gener­ic com­pe­ti­tion to its opi­oid ad­dic­tion treat­ment Sub­ox­one, halt­ing a tri­al sched­uled to be­gin on Oct. 30.

As part of the agree­ment with di­rect pur­chasers who were part of the mul­ti-dis­trict lit­i­ga­tion, In­di­v­ior will pay out the $385 mil­lion in No­vem­ber from its ex­ist­ing cash. The com­pa­ny will al­so take a charge of $228 mil­lion in the third quar­ter and ex­clude that from its ad­just­ed earn­ings.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.